title: Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
abstract: The treatment of patients with chronic lymphocytic leukemia (CLL), an indolent B-cell lymphoma is in the midst of a transformation. There are a large number of promising new therapeutic agents and cellular therapies being studied which exhibit remarkable activity, favorable toxicity profiles, convenient administration schedules, and treatment options are rapidly expanding. The recent advances in the management of CLL exemplify the value of translational medicine. This review highlights key aspects of B-cell receptor (BCR) signaling in relation to novel inhibitors of the BCR signaling pathway, currently at various stages of preclinical and clinical development.
authors: Center for Chronic Lymphocytic Leukemia and Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA.
authors: Anthony
authors: A
authors: Mato
authors: Center for Chronic Lymphocytic Leukemia and Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA.
authors: Shekeab
authors: S
authors: Jauhari
authors: Center for Chronic Lymphocytic Leukemia and Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA.
authors: Stephen J
authors: SJ
authors: Schuster
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005786:Gene Expression Regulation; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011947:Receptors, Antigen, B-Cell / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D011947:Receptors, Antigen, B-Cell